We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+6.56%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
10 Year Est. Return
AUM
$204M
AUM Growth
+$8.99M
Cap. Flow
+$17.5M
Cap. Flow %
8.56%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$17.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$99.4M 48.67%
5,500,007
DSGN icon
2
Design Therapeutics
DSGN
$915M
$78.8M 38.55%
5,626,476
NKTX icon
3
Nkarta
NKTX
$167M
$16.4M 8.04%
+1,333,333
New +$17.5M
EFTR
4
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$9.69M 4.74%
272,885

Similar funds

SR One Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, SR One Capital Management held 4 positions worth $204M, up 4.6% from $195M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SR One Capital Management deployed $17.5M of net new capital in Q2 2022, opening 1 new position. Its largest new stake was Nkarta: 1,333,333 shares worth $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q2 2022 buy was Nkarta: 1,333,333 shares worth $16.4M.
  • SR One Capital Management's ten largest holdings make up 100% of its $204M portfolio in Q2 2022.
  • SR One Capital Management opened 1 new position and closed 0 in Q2 2022.
  • SR One Capital Management's portfolio value rose 4.6% quarter-over-quarter to $204M.

Based on SR One Capital Management's 13F filing for Q2 2022, filed 2 Aug 2022.